And then on -- given the 505(b)(2) pathway, should we expect any differences in the label for YUTREPIA versus TYVASO DPI? I know in the past you've mentioned demonstrating titration to 3 times ...

Trevi Therapeutics (TRVI) reported a net loss of $11.4 million for the fourth quarter of 2024, reflecting an increase from $7.8 million in the same period of 2023. The company’s earnings per ...

Trevi Therapeutics (TRVI) reported a net loss of $11.4 million for the fourth quarter of 2024, reflecting an increase from $7.8 million in the same period of 2023. The company’s earnings per share ...

I think, Biogen and Acyte are really the ones that are pushing the envelope on, you know, not only the evidence, but also expanded label for ... with a revised titration schedule.

Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States Department of Pharmacology, University of ...

Red labels represent proteins whose solubility change in R156X ... Scale bar, 20 μm. (D) Kaplan-Meier survival curve of MNs survival following MG132 or DMSO control. 150 cells tracked per condition, ...

Results Median nocturnal SpO 2 values ranged between 98% and 99% over the first 2 years of life and the CF reference-curves shift right by 1% between 2 weeks and 3 months. CF reference-curves did not ...